股东会召开日期：2025年6月3日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 证券代码：600381 证券简称：*ST 春天 公告编号：2025-023 青海春天药用资源科技股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 3 日 14 点 30 分 召开地点：青海省西宁市城北区生物园区经二路 12 号 4 楼会议室 (一)股东会类型和届次 2024年年度股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 3 日 至2025 年 6 月 3 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9 ...

股票代码：600381 股票简称：*ST 春天 公告编号：2025-022 2025 年 5 月 8 日，公司股票再次涨停。截至 2025 年 5 月 8 日收盘，公司股价剔除 大盘整体因素后的实际波动幅度较大。公司特别提醒广大投资者注意二级市场交易风 险，理性决策，审慎投资。 二、生产经营风险 公司于 2025 年 4 月 30 日披露了《2025 年第一季度报告》，2025 年第一季度营业 收入为 8,355.91 万元，同比减少 1.11%；2025 年第一季度归属于上市公司股东的净利 润为 891.81 万元、归属于上市公司股东扣除非经常性损益后的净利润为 904.59 万元。 目前，公司生产经营情况正常，不存在影响公司股票交易价格大幅波动的重大事项。 三、其他风险警示风险 公司 2024 年度的利润总额、净利润或者扣除非经常性损益后的净利润孰低者为负 值且扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入低于 3 亿 元，根据《上海证券交易所股票上市规则》第 9.3.2 条（一）规定，公司股票已于 2025 年 4 月 30 日被实施退市风险警示。 青海春天药用资源科技股份有限公司 关于 ...

股票代码：600381 股票简称：*ST 春天 公告编号：2025-021 青海春天药用资源科技股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 青海春天药用资源科技股份有限公司（以下简称"公司"）股票交易在 2025 年 4 月 30 日、5 月 6 日、5 月 7 日连续 3 个交易日内日收盘价格涨幅偏离值累计达到 12%， 属于股票交易异常波动。 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公告披露 日，除公司已披露事项外，不存在其它应披露而未披露的重大事项。 公司 2024 年度的利润总额、净利润或者扣除非经常性损益后的净利润孰低者 为负值且扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入低于 3 亿元，根据《上海证券交易所股票上市规则》第 9.3.2 条（一）规定，公司股票已 于 2025 年 4 月 30 日被实施退市风险警示。请广大投资者理性投资，注意股票二级市 场的交易风险。 一、股票交易异常波动的具体情况 公司股票交易在 2 ...

对青海春天药用资源科技股份有限公司 《问询函》的回复 西藏荣恩科技有限公司 对青海春天药用资源科技股份有限公司 《问询函》的回复 青海春天药用资源科技股份有限公司: 本人已收到贵司关于股票交易异常波动的《问询函》,并就该《问 询函》所关注事项回复、确认如下: 截至本回复日,本人不存在买卖贵公司股票、不存在涉及贵公司 的应披露而未披露的重大事项,包括但不限于筹划重大资产重组、股 份发行、债务重组、业务重组、资产剥离和资产注入等重大事项。 青海春天药用资源科技股份有限公司: 贵公司关于股票交易异常波动的《问询函》我公司已收悉。我公 司就该《问询函》所关注事项回复、确认如下: 截至本回函日,我公司不存在其他买卖贵公司股票的情况、不存 在涉及贵公司的应披露而未披露的重大事项,包括但不限于筹划重大 资产重组、股份发行、债务重组、业务重组、资产剥离和资产注入等 重大事项。 专此回复。 专此回复。 回复人:肖融 2025年5月7日 ...

Market Overview - The Shanghai Composite Index closed at 3342.67 points, above the annual line, with a gain of 0.80% [1] - The total trading volume of A-shares reached 15050.72 billion yuan [1] Stocks Breaking Annual Line - A total of 98 A-shares have surpassed the annual line today, with notable stocks including Jinpu Titanium, Sanxiang Impression, and Houpu Co., which have deviation rates of 9.12%, 8.94%, and 7.94% respectively [1] - Stocks with smaller deviation rates that just crossed the annual line include ChuanTou Energy, Hongta Securities, and Jinbin Development [1] Top Stocks by Deviation Rate - Jinpu Titanium (000545) saw a price increase of 9.81% with a turnover rate of 6.51%, latest price at 2.35 yuan, deviation rate of 9.12% [1] - Sanxiang Impression (000863) increased by 10.14% with a turnover rate of 3.85%, latest price at 4.02 yuan, deviation rate of 8.94% [1] - Houpu Co. (300471) rose by 8.78% with a turnover rate of 10.22%, latest price at 9.91 yuan, deviation rate of 7.94% [1] Additional Stocks with Notable Performance - Bojie Co. (002975) increased by 9.99% with a turnover rate of 3.33%, latest price at 32.81 yuan, deviation rate of 7.25% [1] - Hangxin Technology (300424) rose by 6.12% with a turnover rate of 11.08%, latest price at 15.78 yuan, deviation rate of 5.43% [1] - Other notable stocks include Zhonghang Shenfei (600760) and Hongye Futures (001236) with deviation rates of 4.48% and 3.52% respectively [1]

Core Viewpoint - ST Qinghai Spring (ST春天) faces significant challenges as it transitions to a *ST designation due to failing to meet the revenue threshold of 3 billion yuan, despite a 26.36% year-on-year revenue increase to 270 million yuan in 2024 [2][4]. Financial Performance - In 2024, ST Qinghai Spring reported a revenue of 270 million yuan, with a net loss of 198 million yuan after excluding non-core business income [2]. - The first quarter of 2024 showed a revenue of 83.56 million yuan, a slight decline of 1.11% year-on-year, but a net profit of 8.92 million yuan, indicating a turnaround [2][3]. Revenue Concerns - The company was criticized for a "last-minute revenue boost" in Q4 of the previous year, raising questions about the legitimacy of its revenue recognition practices [4][5]. - The fourth quarter revenue reportedly exceeded 100 million yuan, which was seen as an attempt to avoid delisting [4][6]. Market Strategy and Challenges - ST Qinghai Spring's flagship product, "Tinghua Wine," has struggled to regain market traction following a scandal involving false advertising, which led to significant penalties and a temporary market withdrawal [8][9]. - The company has shifted its marketing strategy to emphasize scarcity and high pricing, with plans to limit annual production to 30,000 tons [9][12]. Business Segmentation - The wine business accounted for approximately 17.53% of ST Qinghai Spring's total revenue, with a significant year-on-year decline of 44.05% in wine revenue [14][15]. - The company continues to rely on traditional products like Cordyceps for revenue stability, as the wine segment remains in its early stages of development [17]. Future Outlook - Analysts express skepticism about the wine segment's ability to significantly contribute to the company's financial recovery, given the current market conditions and the limited number of distributors [16][17]. - The company plans to introduce new products and enhance brand communication, but the success of these initiatives remains uncertain [16].

Core Viewpoint - The A-share ST sector is experiencing a strong performance, with over 40 stocks including *ST Jingang, *ST Tianwei, *ST Bodao, *ST Gaohong, *ST Zhongdi, *ST Chuntian, and ST Ruihe hitting the daily limit up [1] Group 1 - The ST sector is showing significant strength in the A-share market [1] - More than 40 stocks in the ST category have reached their daily trading limit [1]

Financial Performance - In 2024, the company achieved total revenue of 270 million yuan, a year-on-year increase of 26.36% [2][3] - The net profit attributable to shareholders was a loss of 199.77 million yuan, an improvement from a loss of 268.65 million yuan in the previous year [2][3] - The net profit excluding non-recurring items was a loss of 161.57 million yuan, compared to a loss of 243.67 million yuan in the previous year [2][3] - The net cash flow from operating activities was 80.97 million yuan, a significant increase of 238.56% year-on-year [2][3] Key Ratios - The basic earnings per share for 2024 was -0.34 yuan, with a weighted average return on equity of -17.26% [2][3] - The company's price-to-earnings ratio (TTM) is approximately -8.71 times, while the price-to-book ratio (LF) is about 1.68 times, and the price-to-sales ratio (TTM) is around 6.41 times [2][3] Asset and Liability Changes - As of the end of 2024, the company's net assets attributable to shareholders decreased by 18.38% compared to the previous year [3] - Inventory decreased by 41.44%, while cash and cash equivalents increased by 20.29% [51] - Contract liabilities increased by 106.8%, while lease liabilities decreased by 69.72% [54] Research and Development - The company invested 14.96 million yuan in research and development in 2024, a year-on-year increase of 28.54%, representing 5.54% of total revenue [61] Shareholder Structure - The largest shareholder, Tibet Rong'en Technology Co., Ltd., holds 32.13% of the shares, with significant pledges on their holdings [65] - New shareholders include Hu Zhenmin, Zhu Qiulian, Zhang Qian, and Ye Lingxiang, replacing previous shareholders [66]

Core Insights - A-share listed companies demonstrated strong resilience in 2024, with total operating revenue reaching 62.33 trillion yuan, a year-on-year increase of 0.57%, and net profit attributable to shareholders of 5.06 trillion yuan, up 1.05% [1][2] - The growth was primarily driven by advancements in artificial intelligence (AI) technology, which significantly boosted demand in sectors such as GPU, PCB, and storage chips [2][3] - Despite overall growth, non-financial companies faced challenges, with a slight decline in revenue and a notable drop in net profit [1][3] Financial Performance - Among the 5402 listed companies, 4029 reported positive earnings, with 548 companies achieving over 100% growth in net profit [2] - The chemical company Zhengdan achieved a remarkable 119-fold increase in net profit, driven by soaring TMA prices due to supply-demand imbalances [2][3] - The semiconductor sector saw significant profit increases, with companies like Zhaoyi Innovation and Weir Shares reporting net profit growth of 584.21% and 498.11%, respectively [3] Sector Analysis - The AI sector is identified as a key growth driver, with companies in the GPU, PCB, and optical module industries experiencing substantial performance improvements [2][3] - The consumer electronics market is also rebounding, with a reported 5.6% year-on-year increase in smartphone shipments in China [3][4] International Expansion - A total of 3653 listed companies reported overseas revenue of 9.43 trillion yuan, accounting for approximately 20% of their total revenue [6][7] - Companies like Luxshare Precision and BYD achieved over 100 billion yuan in overseas revenue, with notable growth in emerging markets [6][7] - The internationalization strategies include local market investments and partnerships, particularly in Africa and the Middle East [7][8] Challenges and Losses - Despite overall positive performance, 124 companies reported net losses exceeding 1 billion yuan, with the real estate sector being particularly affected [9][10] - Vanke A led the loss rankings with a staggering 494.78 billion yuan loss, highlighting the difficulties faced in the real estate market [9][10] - The energy sector, including solar and lithium companies, also reported significant losses due to overcapacity and intensified competition [10] Regulatory Environment - The introduction of stricter delisting regulations is expected to normalize the delisting process, with 52 companies delisted in 2024 [11][12] - New rules include higher thresholds for financial delisting criteria, aiming to enhance market stability and protect investor interests [11][12]

Core Viewpoint - Qinghai Spring (600381) has shown significant resilience in its operations, with a notable increase in revenue and a positive shift in profitability, leading to a strong market response reflected in its stock price surge on April 30 [1][4]. Financial Performance - In 2024, the company reported total revenue of 270 million, representing a nearly 30% year-on-year growth [5]. - The net cash flow from operating activities reached 81 million, marking the best level since 2018 [5]. - The first quarter of 2025 saw revenue of approximately 84 million, achieving a new high over the last four quarters, with net profit turning positive after a series of losses since 2020 [9]. Strategic Initiatives - The company is actively addressing intensified industry competition by increasing product promotion and market expansion efforts in the liquor and health sectors, with sales expenses amounting to 147 million, accounting for 54.65% of total revenue [8]. - Qinghai Spring has made significant advancements in its liquor segment, obtaining patents for innovative brewing methods and health-oriented product formulations, which are expected to enhance product quality and market appeal [8]. Future Outlook - The company plans to focus on promoting sales of health products such as Cordyceps and lung health tablets in 2025, while continuing to drive innovation in the liquor sector [10]. - Qinghai Spring aims to respond to national initiatives for developing emerging industries and enhancing production capabilities, seeking to establish new business segments for sustainable growth [10].